Important Considerations for Treatment Sequencing in CLL
This video discusses the importance of sequencing therapies based on patient-specific factors. cBTKi and BCL-2i are 1L and 2L treatment options, followed by non-covalent BTKi and CAR T-cell therapy as options for cBTKi and BCL-2i dual exposed patients.
Date of Last Review: May 13, 2025
Document Number: VV-MED-167879
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice